Janus Henderson Group PLC Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

Janus Henderson Group PLC lifted its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 9.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,983,940 shares of the company's stock after buying an additional 425,421 shares during the period. Janus Henderson Group PLC owned about 5.26% of Edgewise Therapeutics worth $133,044,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Barclays PLC grew its position in shares of Edgewise Therapeutics by 291.0% during the 3rd quarter. Barclays PLC now owns 119,350 shares of the company's stock valued at $3,186,000 after acquiring an additional 88,826 shares during the period. Franklin Resources Inc. lifted its stake in Edgewise Therapeutics by 84.2% in the 3rd quarter. Franklin Resources Inc. now owns 45,223 shares of the company's stock worth $1,207,000 after purchasing an additional 20,674 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Edgewise Therapeutics by 146.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 158,506 shares of the company's stock valued at $4,231,000 after purchasing an additional 94,147 shares during the last quarter. Moody Aldrich Partners LLC grew its position in shares of Edgewise Therapeutics by 24.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 187,932 shares of the company's stock valued at $5,018,000 after purchasing an additional 36,775 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Edgewise Therapeutics by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,077 shares of the company's stock valued at $536,000 after purchasing an additional 2,042 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Royal Bank of Canada dropped their price target on Edgewise Therapeutics from $56.00 to $52.00 and set an "outperform" rating for the company in a research note on Thursday, April 3rd. Piper Sandler reiterated an "overweight" rating and set a $51.00 price objective on shares of Edgewise Therapeutics in a research report on Wednesday, April 2nd. Stifel Nicolaus initiated coverage on shares of Edgewise Therapeutics in a report on Wednesday, January 22nd. They issued a "hold" rating and a $30.00 target price on the stock. Scotiabank lowered Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and dropped their price target for the stock from $50.00 to $14.00 in a research report on Wednesday, April 2nd. Finally, Guggenheim assumed coverage on shares of Edgewise Therapeutics in a research note on Wednesday, April 30th. They set a "buy" rating and a $41.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Edgewise Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $40.22.

Edgewise Therapeutics Stock Performance

NASDAQ:EWTX traded up $0.33 during trading hours on Friday, reaching $14.78. The company's stock had a trading volume of 1,281,742 shares, compared to its average volume of 1,166,956. The stock has a 50 day moving average price of $17.22 and a two-hundred day moving average price of $25.08. The company has a market capitalization of $1.55 billion, a P/E ratio of -9.85 and a beta of 0.36. Edgewise Therapeutics, Inc. has a 12 month low of $10.60 and a 12 month high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.02. As a group, analysts predict that Edgewise Therapeutics, Inc. will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CMO Joanne M. Donovan sold 5,187 shares of the company's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total value of $85,326.15. Following the sale, the chief marketing officer now directly owns 21,588 shares of the company's stock, valued at $355,122.60. This represents a 19.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alan J. Russell sold 1,551 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $16.45, for a total transaction of $25,513.95. Following the transaction, the insider now directly owns 18,521 shares of the company's stock, valued at approximately $304,670.45. This trade represents a 7.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,258 shares of company stock worth $234,544 in the last 90 days. Insiders own 23.20% of the company's stock.

Edgewise Therapeutics Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.